CD19 and Miyoshi myopathy: As shown in Figure A2, higher any grade CRS event incidences were observed in CD19-ALL (88%; 95% CI, 86–89%), CD19-NHL (78%; 95% CI, 62–94%), CD20-NHL (79%; 95% CI, 37–121%), CD20-ALL (80%; 95% CI, 77–83%), CD22-ALL (76%; 95% CI, 72–80%), BCMA-MM (74%; 95% CI, 56–91%), and CEA (50%; 95% CI, 48–148%).